-

“Thank you, President Biden” - Owens & Minor Welcomes President Biden Strategy on COVID Response

RICHMOND, Va.--(BUSINESS WIRE)--Today, Edward Pesicka, President and CEO of Owens & Minor, a leading manufacturer of HALYARD* branded Personal Protective Equipment (PPE), welcomed the announcement from President Biden of the National Strategy for the COVID-19 Response and Pandemic Preparedness.

“Thank you, President Biden,” said Pesicka. “When Americans mask up during this crucial phase in the pandemic, we want them to reach for a Made in America mask and other PPE whenever possible. Our 15,000 teammates have been working continuously throughout the pandemic to answer the call of our country. We welcome President Biden’s thoughtful and comprehensive approach to combating this pandemic and we look forward to working with the administration.”

As one of the world’s largest vertically integrated manufacturers of a full range of healthcare PPE, and a leading distributor of medical supplies, Owens & Minor delivered more than 12 billion PPE units in the United States in 2020. Owens & Minor owns and operates an Americas-based manufacturing footprint – manufacturing our own raw materials in North Carolina and converting that raw material into N95 respirators, isolation gowns, surgical gowns, ear loop masks and other PPE in its own plants in Texas, Mexico and Honduras. Owens & Minor is also one of the very few U.S. companies to manufacture nitrile gloves at large scale within its own factory in Southeast Asia. “We offer our large-scale manufacturing expertise to the administration,” added Pesicka.

In 2020, Owens & Minor made significant investments in capital, operational efficiency, rate of operation, and expanded its workforce to ramp up production and delivery of PPE. These investments were supplemented by a Technology Investment Agreement (TIA) from the U.S. Department of Defense (DoD).

As a result of these combined efforts, Owens & Minor achieved:

  • More than 1000% increase in N95 respirator production at three Americas locations
  • Nearly 100% increase in surgical and procedure mask production
  • More than 600% increase in face shields production
  • A 300% increase in isolation gown production

Owens & Minor was also selected as one of five companies to work with the Department of Health and Human Services (HHS) to produce approximately 600 million N95 respirator masks for the U.S. market.

###

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services to deliver significant and sustained value across the breadth of the industry – from acute care to patients in their home. Aligned to its Mission of Empowering Our Customers to Advance HealthcareTM, more than 15,000 global teammates serve over 4,000 healthcare industry customers. A vertically-integrated, predominantly Americas-based footprint enables Owens & Minor to reliably supply its self-manufactured surgical and PPE products. This seamless value chain integrates with a portfolio of products representing 1,200 branded suppliers. Operating continuously since 1882 from its headquarters in Richmond, Virginia, Owens & Minor has grown into a FORTUNE 500 company with operations located across North America, Asia, Europe and Latin America. For more information about Owens & Minor, visit owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.

Contacts

Heather Sabharwal
202-423-5879
media@owens-minor.com

Owens & Minor

NYSE:ACH
Details
Headquarters: Richmond, VA
CEO: Edward Pesicka
Employees: 6000
Organization: PUB

Release Summary
Ready to assist Biden Administration COVID strategy
Release Versions

Contacts

Heather Sabharwal
202-423-5879
media@owens-minor.com

More News From Owens & Minor

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce o...

Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) designed to protect long-term shareholder value by facilitating the Company’s ability to preserve its net operating loss carryforwards (“NOLs”) and certain other tax attributes. A company generally experiences an ownership change if the percentage of the value of its stock owned by certain “5-percen...

Accendra Health Reports Second Quarter 2026 Financial Results

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the second quarter ended June 30, 2026. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. “Throughout the second quarter, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payor exi...
Back to Newsroom